Cargando…

Clinical outcome in lung cancer with a second malignancy: The time sequence matters

The aim of the study was to determine the clinical outcome of lung cancer patients with a secondary malignancy according to the time sequence between the lung cancer and the secondary malignancy. Retrospective review of all lung cancer patients with any secondary cancer treated from June 2004 to Jul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Ming-Shian, Chen, Miao-Fen, Huang, Yao-Kuang, Liu, Hui-Ping, Tsai, Ying-Huang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089105/ https://www.ncbi.nlm.nih.gov/pubmed/27787376 http://dx.doi.org/10.1097/MD.0000000000005203

Ejemplares similares

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022)

Incidence of Second Primary Malignancies Following Colorectal Cancer: A Distinct Pattern of Occurrence Between Colon and Rectal Cancers and Association of Co-Morbidity with Second Primary Malignancies in a Population-Based Cohort of 98,876 Patients in Taiwan
por: Lee, Yu-Ting, et al.
Publicado: (2015)

Second primary malignancy in patients with esophageal adenocarcinoma and squamous cell carcinoma
por: Zhang, Guoqing, et al.
Publicado: (2019)

Better survival and prognosis in SCLC survivors after combined second primary malignancies: A SEER database-based study
por: Wang, Silin, et al.
Publicado: (2023)

Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report
por: Vanni, Irene, et al.
Publicado: (2016)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Network module function enrichment analysis of lung squamous cell carcinoma and lung adenocarcinoma
por: Li, Piaopiao, et al.
Publicado: (2022)

Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: A meta-analysis
por: Hu, Yongqi, et al.
Publicado: (2022)

Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis
por: Xin, Wen-Xiu, et al.
Publicado: (2018)

Recurrence Risk Factors Analysis for Stage I Non-small Cell Lung Cancer
por: Wu, Ching-Feng, et al.
Publicado: (2015)

Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection
por: Wu, Ching-Yang, et al.
Publicado: (2015)

Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the Prognosis
por: Wu, Ching-Yang, et al.
Publicado: (2015)

Gastrointestinal stromal tumors (GISTs) and second malignancies: A novel “sentinel tumor”? A monoinstitutional, STROBE-compliant observational analysis
por: Rodriquenz, Maria Grazia, et al.
Publicado: (2016)

Comparison between different treatment regimens of vascular targeting drug to malignant pleural effusion in patients with lung cancer: A Bayesian network meta-analysis
por: Huang, Peng, et al.
Publicado: (2023)

The clinicopathological features of second primary cancer in patients with prior breast cancer
por: Liu, YiHui, et al.
Publicado: (2017)

Circular RNA expression profile in peripheral whole blood of lung adenocarcinoma by high: Throughput sequencing
por: Mu, Yinyu, et al.
Publicado: (2019)

XXYLT1 methylation contributes to the occurrence of lung adenocarcinoma: Methylation and lung adenocarcinoma
por: Zeng, Hui, et al.
Publicado: (2021)

Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC): A meta-analysis of 7 randomized controlled trials
por: Li, Qing, et al.
Publicado: (2017)

Is chronic kidney disease an adverse factor in lung cancer clinical outcome? A propensity score matching study
por: Lu, Ming‐Shian, et al.
Publicado: (2017)

The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients: A meta-analysis
por: Huang, Ying, et al.
Publicado: (2020)

Varied clinical significance of ATP-binding cassette C sub-family members for lung adenocarcinoma
por: Zhang, Linbo, et al.
Publicado: (2021)

A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer
por: Liu, Xin-Xiu, et al.
Publicado: (2022)

Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma
por: Xin, Yong, et al.
Publicado: (2016)

Notch Signaling Components: Diverging Prognostic Indicators in Lung Adenocarcinoma
por: Liu, Zhi-Yan, et al.
Publicado: (2016)

Targeted next-generation sequencing of malignant peripheral nerve sheath tumor of the pterygopalatine fossa with intracranial metastatic recurrence
por: Bao, Xinjie, et al.
Publicado: (2018)

Malignant adenomyoepithelioma of the breast: A case report
por: Zhang, Zhihao, et al.
Publicado: (2021)

Cancer Risk in Patients With Inflammatory Systemic Autoimmune Rheumatic Diseases: A Nationwide Population-Based Dynamic Cohort Study in Taiwan
por: Yu, Kuang-Hui, et al.
Publicado: (2016)

Metachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach: A Case Report
por: Jiang, Meng-jie, et al.
Publicado: (2015)

Somatic SDHA mutations in paragangliomas in siblings: Case report of 2 cases
por: Huang, Yen-Chun, et al.
Publicado: (2020)

Sera total oxidant/antioxidant status in lung cancer patients
por: Xiang, Miao, et al.
Publicado: (2019)

Lung cancer outcome in the setting of chronic kidney disease: Does the glomerular filtration estimation formula matter?
por: Lu, Ming‐Shian, et al.
Publicado: (2018)

A meta-analysis on the relationship of exosomes and the prognosis of lung cancer
por: Xiang, Hui, et al.
Publicado: (2021)

Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI: A case report
por: Chen, Hui Jun, et al.
Publicado: (2021)

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis
por: Huang, Lei, et al.
Publicado: (2019)

Risk factors of lymph node metastasis in lung squamous cell carcinoma of 3 cm or less in diameter
por: Huang, Lijian, et al.
Publicado: (2017)

Single institute experience of intraoperative radiation therapy in early-stage breast cancer
por: Chi, Mau-Shin, et al.
Publicado: (2021)

Doublet Versus Single Agent as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis of 10 Randomized Controlled Trials
por: Zhang, Yong, et al.
Publicado: (2016)

Predictive Value of (18)F-FDG PET and CT Morphologic Features for Recurrence in Pathological Stage IA Non-Small Cell Lung Cancer
por: Ko, Kai-Hsiung, et al.
Publicado: (2015)

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer
por: Anzai, Masaki, et al.
Publicado: (2017)

Prognostic value of the systemic inflammation response index in human malignancy: A meta-analysis
por: Wei, Lishuang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q6vbkpnj30ns71ng7pq55gmclg